BRAF V600E

CI-VAR-00004575Explore in graph →NP_004324.2:p.Val600GluNM_004333.4:c.1799T>AClinVar 13961 CIViC 12 rs113488022

Curated evidence

Evidence by cancer (259 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 151–200 of 259 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma50
BRAF V600E	Dabrafenib	Predictive	B	Supports Sensitivity Response	—	submitted	EID2126 Patients with BRAF mutations who were treated with the specific RAF inhibitor dabrafenib had an improved overall survival (P<0.003) compared to untreated patients with BRAF mutations. Patients harbori… (full text at CIViC) PMID 21343559 · Long et al., 2011 · Open in CIViC	civic
BRAF V600E	Dabrafenib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2127 Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy. PMID 20818844 · Flaherty et al., 2010 · Open in CIViC	civic
BRAF V600E	Dabrafenib

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.